Male sex [2], long‐term TKI treatment, and DMR duration [27], deeper molecular remission status [28], immune cell activation status [11, 15] and a lower Sokal risk score [2] are favorable prognostic factors for TFR1 in patients with CML‐CP; however, we did not identify any of these as favorable prognostic factors for sustained TFR1. Here, TFRC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.